The exploration of the use of placenta in Diabetic Ulcer Disease: A Systematic Review
Main Article Content
Abstract
This paper seeks to provide a comprehensive review of the utilization of placental tissue therapies in addressing the challenges posed by diabetic foot ulcers (DFUs). A systematic review approach was employed, utilizing the PubMed database to identify relevant research papers. Following the initial search, a rigorous screening process was undertaken, comprising two rounds of screening to ensure the inclusion of relevant studies. The review showed that placental tissue therapies are effective for diabetic foot ulcers (DFUs). They can be applied topically, injected, or implanted, leading to faster wound healing and tissue regeneration. Studies found quicker closure of wounds, shorter healing times, and better outcomes with these treatments. Placental tissues contain mesenchymal stem cells and growth factors, making them effective for diabetic foot ulcers management. They offer a promising way to speed up wound healing and enhance patient outcomes. Further research is warranted to validate these findings and explore optimal treatment protocols for maximizing the therapeutic benefits of placental tissue therapies in diabetic foot ulcers management.
Article Details
How to Cite
AREZINA, Daniela J.; LI, Dan.
The exploration of the use of placenta in Diabetic Ulcer Disease: A Systematic Review.
Medical Research Archives, [S.l.], v. 12, n. 12, jan. 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/5978>. Date accessed: 06 jan. 2025.
doi: https://doi.org/10.18103/mra.v12i12.5978.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Sledge I, Maislin D, Bernarducci D, Snyder R, Serena TE. Use of a dual-layer amniotic membrane in the treatment of diabetic foot ulcers: an observational study. J Wound Care. 2020;29(Sup9):S8-S12. doi:10.12968/jowc.2020.29.Sup9.S8
2. Haugh AM, Witt JG, Hauch A, et al. Amnion Membrane in Diabetic Foot Wounds: A Meta-analysis. Plast Reconstr Surg Glob Open. 2017;5(4):e1302. doi:10.1097/GOX.0000000000001302
3. Reyzelman AM, Vartivarian M, Danilkovitch A, Saunders MC. A Prospective, Single-center, Open-label Case Series Evaluating the Clinical Outcomes of Lyopreserved Placental Membrane Containing Viable Cells in the Treatment of Chronic Wounds. Wounds Compend Clin Res Pract. 2019;31(4):97-102.
4. Oesman I, Dhamar Hutami W. Gamma-treated placental amniotic membrane allograft as the adjuvant treatment of unresponsive diabetic ulcer of the foot. Int J Surg Case Rep. 2020;66:313-318. doi:10.1016/j.ijscr.2019.12.033
5. Galiano RD, Orgill DP, Armstrong DG, Glat PM, Carter MJ, Zelen CM. A Prospective Multicenter Study of a Weekly Application Regimen of Viable Human Amnion Membrane Allograft in the Management of Nonhealing Diabetic Foot Ulcers. Plast Reconstr Surg Glob Open. 2023;11(10):e5291. doi:10.1097/GOX.0000000000005291
6. Sabolinski ML, Capotorto JV. Comparative effectiveness of a human fibroblast-derived dermal substitute and a viable cryopreserved placental membrane for the treatment of diabetic foot ulcers. J Comp Eff Res. 2019;8(14):1229-1238. doi:10.2217/cer-2019-0001
7. Wang H, Chen L, Liu Y, et al. Implantation of placenta-derived mesenchymal stem cells accelerates murine dermal wound closure through immunomodulation. Am J Transl Res. 2016;8(11):4912-4921.
8. Lavery L, Fulmer J, Shebetka K, et al. The efficacy and safety of Grafix (R) for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J. 2014;11. doi:10.1111/iwj.12329
9. Yu X, Liu P, Li Z, Zhang Z. Function and mechanism of mesenchymal stem cells in the healing of diabetic foot wounds. Front Endocrinol. 2023;14:1099310. doi:10.3389/fendo.2023.1099310
10. Brantley JN, Verla TD. Use of Placental Membranes for the Treatment of Chronic Diabetic Foot Ulcers. Adv Wound Care. 2015;4(9):545-559. doi:10.1089/wound.2015.0634
11. Lakmal K, Basnayake O, Hettiarachchi D. Systematic review on the rational use of amniotic membrane allografts in diabetic foot ulcer treatment. BMC Surg. 2021;21(1):87. doi:10.1186/s12893-021-01084-8
12. Meamar R, Ghasemi-Mobarakeh L, Norouzi MR, Siavash M, Hamblin MR, Fesharaki M. Improved wound healing of diabetic foot ulcers using human placenta-derived mesenchymal stem cells in gelatin electrospun nanofibrous scaffolds plus a platelet-rich plasma gel: A randomized clinical trial. Int Immunopharmacol. 2021;101(Pt B):108282. doi:10.1016/j.intimp.2021.108282
13. DiDomenico LA, Orgill DP, Galiano RD, et al. A Retrospective Crossover Study of the Use of Aseptically Processed Placental Membrane in the Treatment of Chronic Diabetic Foot Ulcers. Wounds Compend Clin Res Pract. 2017;29(10):311-316.
14. Tettelbach WH, Cazzell SM, Hubbs B, Jong JLD, Forsyth RA, Reyzelman AM. The influence of adequate debridement and placental-derived allografts on diabetic foot ulcers. J Wound Care. 2022;31(Sup9):S16-S26. doi:10.12968/jowc.2022.31.Sup9.S16
15. Snyder D, Sullivan N, Margolis D, Schoelles K. Skin Substitutes for Treating Chronic Wounds. Agency for Healthcare Research and Quality (US); 2020. Accessed October 31, 2024. http://www.ncbi.nlm.nih.gov/books/NBK554220/
16. Wu SC, Pollak R, Frykberg RG, et al. Safety and efficacy of intramuscular human placenta-derived mesenchymal stromal-like cells (cenplacel [PDA-002]) in patients who have a diabetic foot ulcer with peripheral arterial disease. Int Wound J. 2017;14(5):823-829. doi:10.1111/iwj.12715
17. DaVanzo J, Hartzman A, Surfield C, Dobson A. Cryopreserved Placental Membrane Allograft Reduces the Likelihood of Developing a New or Recurring Foot Ulcer and All-Cause Mortality in Diabetic Patients When Compared with Other Cellular- and Tissue-Based Products. Adv Wound Care. 2023;12(4):169-176. doi:10.1089/wound.2021.0123
18. Garoufalis M, Tettelbach W. Expandable dehydrated human umbilical cord allograft for the management of nonhealing lower extremity wounds in patients with diabetes: a case series. Wounds Compend Clin Res Pract. 2022;34(9):E91-E95. doi:10.25270/wnds/21126
19. Luck J, Rodi T, Geierlehner A, Mosahebi A. Allogeneic Skin Substitutes Versus Human Placental Membrane Products in the Management of Diabetic Foot Ulcers: A Narrative Comparative Evaluation of the Literature. Int J Low Extrem Wounds. 2019;18(1):10-22. doi:10.1177/1534734618818301
20. Frykberg RG, Gibbons GW, Walters JL, Wukich DK, Milstein FC. A prospective, multicentre, open-label, single-arm clinical trial for treatment of chronic complex diabetic foot wounds with exposed tendon and/or bone: positive clinical outcomes of viable cryopreserved human placental membrane. Int Wound J. 2017;14(3):569-577. doi:10.1111/iwj.12649
21. Oropallo A, Goodwin A, Morrissey M, Del Pin C, Rao A. Human Amnion Chorion Membrane Allografts in the Treatment of Chronic Diabetic Foot Ulcers: A Literature Review. Adv Skin Wound Care. 2021;34(4):1-7. doi:10.1097/01.ASW.0000734388.08779.e8
22. Glat P, Orgill DP, Galiano R, et al. Placental Membrane Provides Improved Healing Efficacy and Lower Cost Versus a Tissue-Engineered Human Skin in the Treatment of Diabetic Foot Ulcerations. Plast Reconstr Surg Glob Open. 2019;7(8):e2371. doi:10.1097/GOX.0000000000002371
23. Lavery L, Fulmer J, Shebetka KA, et al. Open-label Extension Phase of a Chronic Diabetic Foot Ulcer Multicenter, Controlled, Randomized Clinical Trial Using Cryopreserved Placental Membrane. Wounds Compend Clin Res Pract. 2018;30(9):283-289.
24. Hanselman AE, Lalli TAJ, Santrock RD. Topical Review: Use of Fetal Tissue in Foot and Ankle Surgery. Foot Ankle Spec. 2015;8(4):297-304. doi:10.1177/1938640015578513
25. Raspovic KM, Wukich DK, Naiman DQ, et al. Effectiveness of viable cryopreserved placental membranes for management of diabetic foot ulcers in a real world setting. Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc. 2018;26(2):213-220. doi:10.1111/wrr.12635
26. Ananian CE, Dhillon YS, Van Gils CC, et al. A multicenter, randomized, single-blind trial comparing the efficacy of viable cryopreserved placental membrane to human fibroblast-derived dermal substitute for the treatment of chronic diabetic foot ulcers. Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc. 2018;26(3):274-283. doi:10.1111/wrr.12645
2. Haugh AM, Witt JG, Hauch A, et al. Amnion Membrane in Diabetic Foot Wounds: A Meta-analysis. Plast Reconstr Surg Glob Open. 2017;5(4):e1302. doi:10.1097/GOX.0000000000001302
3. Reyzelman AM, Vartivarian M, Danilkovitch A, Saunders MC. A Prospective, Single-center, Open-label Case Series Evaluating the Clinical Outcomes of Lyopreserved Placental Membrane Containing Viable Cells in the Treatment of Chronic Wounds. Wounds Compend Clin Res Pract. 2019;31(4):97-102.
4. Oesman I, Dhamar Hutami W. Gamma-treated placental amniotic membrane allograft as the adjuvant treatment of unresponsive diabetic ulcer of the foot. Int J Surg Case Rep. 2020;66:313-318. doi:10.1016/j.ijscr.2019.12.033
5. Galiano RD, Orgill DP, Armstrong DG, Glat PM, Carter MJ, Zelen CM. A Prospective Multicenter Study of a Weekly Application Regimen of Viable Human Amnion Membrane Allograft in the Management of Nonhealing Diabetic Foot Ulcers. Plast Reconstr Surg Glob Open. 2023;11(10):e5291. doi:10.1097/GOX.0000000000005291
6. Sabolinski ML, Capotorto JV. Comparative effectiveness of a human fibroblast-derived dermal substitute and a viable cryopreserved placental membrane for the treatment of diabetic foot ulcers. J Comp Eff Res. 2019;8(14):1229-1238. doi:10.2217/cer-2019-0001
7. Wang H, Chen L, Liu Y, et al. Implantation of placenta-derived mesenchymal stem cells accelerates murine dermal wound closure through immunomodulation. Am J Transl Res. 2016;8(11):4912-4921.
8. Lavery L, Fulmer J, Shebetka K, et al. The efficacy and safety of Grafix (R) for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J. 2014;11. doi:10.1111/iwj.12329
9. Yu X, Liu P, Li Z, Zhang Z. Function and mechanism of mesenchymal stem cells in the healing of diabetic foot wounds. Front Endocrinol. 2023;14:1099310. doi:10.3389/fendo.2023.1099310
10. Brantley JN, Verla TD. Use of Placental Membranes for the Treatment of Chronic Diabetic Foot Ulcers. Adv Wound Care. 2015;4(9):545-559. doi:10.1089/wound.2015.0634
11. Lakmal K, Basnayake O, Hettiarachchi D. Systematic review on the rational use of amniotic membrane allografts in diabetic foot ulcer treatment. BMC Surg. 2021;21(1):87. doi:10.1186/s12893-021-01084-8
12. Meamar R, Ghasemi-Mobarakeh L, Norouzi MR, Siavash M, Hamblin MR, Fesharaki M. Improved wound healing of diabetic foot ulcers using human placenta-derived mesenchymal stem cells in gelatin electrospun nanofibrous scaffolds plus a platelet-rich plasma gel: A randomized clinical trial. Int Immunopharmacol. 2021;101(Pt B):108282. doi:10.1016/j.intimp.2021.108282
13. DiDomenico LA, Orgill DP, Galiano RD, et al. A Retrospective Crossover Study of the Use of Aseptically Processed Placental Membrane in the Treatment of Chronic Diabetic Foot Ulcers. Wounds Compend Clin Res Pract. 2017;29(10):311-316.
14. Tettelbach WH, Cazzell SM, Hubbs B, Jong JLD, Forsyth RA, Reyzelman AM. The influence of adequate debridement and placental-derived allografts on diabetic foot ulcers. J Wound Care. 2022;31(Sup9):S16-S26. doi:10.12968/jowc.2022.31.Sup9.S16
15. Snyder D, Sullivan N, Margolis D, Schoelles K. Skin Substitutes for Treating Chronic Wounds. Agency for Healthcare Research and Quality (US); 2020. Accessed October 31, 2024. http://www.ncbi.nlm.nih.gov/books/NBK554220/
16. Wu SC, Pollak R, Frykberg RG, et al. Safety and efficacy of intramuscular human placenta-derived mesenchymal stromal-like cells (cenplacel [PDA-002]) in patients who have a diabetic foot ulcer with peripheral arterial disease. Int Wound J. 2017;14(5):823-829. doi:10.1111/iwj.12715
17. DaVanzo J, Hartzman A, Surfield C, Dobson A. Cryopreserved Placental Membrane Allograft Reduces the Likelihood of Developing a New or Recurring Foot Ulcer and All-Cause Mortality in Diabetic Patients When Compared with Other Cellular- and Tissue-Based Products. Adv Wound Care. 2023;12(4):169-176. doi:10.1089/wound.2021.0123
18. Garoufalis M, Tettelbach W. Expandable dehydrated human umbilical cord allograft for the management of nonhealing lower extremity wounds in patients with diabetes: a case series. Wounds Compend Clin Res Pract. 2022;34(9):E91-E95. doi:10.25270/wnds/21126
19. Luck J, Rodi T, Geierlehner A, Mosahebi A. Allogeneic Skin Substitutes Versus Human Placental Membrane Products in the Management of Diabetic Foot Ulcers: A Narrative Comparative Evaluation of the Literature. Int J Low Extrem Wounds. 2019;18(1):10-22. doi:10.1177/1534734618818301
20. Frykberg RG, Gibbons GW, Walters JL, Wukich DK, Milstein FC. A prospective, multicentre, open-label, single-arm clinical trial for treatment of chronic complex diabetic foot wounds with exposed tendon and/or bone: positive clinical outcomes of viable cryopreserved human placental membrane. Int Wound J. 2017;14(3):569-577. doi:10.1111/iwj.12649
21. Oropallo A, Goodwin A, Morrissey M, Del Pin C, Rao A. Human Amnion Chorion Membrane Allografts in the Treatment of Chronic Diabetic Foot Ulcers: A Literature Review. Adv Skin Wound Care. 2021;34(4):1-7. doi:10.1097/01.ASW.0000734388.08779.e8
22. Glat P, Orgill DP, Galiano R, et al. Placental Membrane Provides Improved Healing Efficacy and Lower Cost Versus a Tissue-Engineered Human Skin in the Treatment of Diabetic Foot Ulcerations. Plast Reconstr Surg Glob Open. 2019;7(8):e2371. doi:10.1097/GOX.0000000000002371
23. Lavery L, Fulmer J, Shebetka KA, et al. Open-label Extension Phase of a Chronic Diabetic Foot Ulcer Multicenter, Controlled, Randomized Clinical Trial Using Cryopreserved Placental Membrane. Wounds Compend Clin Res Pract. 2018;30(9):283-289.
24. Hanselman AE, Lalli TAJ, Santrock RD. Topical Review: Use of Fetal Tissue in Foot and Ankle Surgery. Foot Ankle Spec. 2015;8(4):297-304. doi:10.1177/1938640015578513
25. Raspovic KM, Wukich DK, Naiman DQ, et al. Effectiveness of viable cryopreserved placental membranes for management of diabetic foot ulcers in a real world setting. Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc. 2018;26(2):213-220. doi:10.1111/wrr.12635
26. Ananian CE, Dhillon YS, Van Gils CC, et al. A multicenter, randomized, single-blind trial comparing the efficacy of viable cryopreserved placental membrane to human fibroblast-derived dermal substitute for the treatment of chronic diabetic foot ulcers. Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc. 2018;26(3):274-283. doi:10.1111/wrr.12645